ADC Linker

Fmoc-Val-Cit-PAB-PNP is a cleavable peptide linker, is a linker for antibody-drug-conjugation (ADC).

Fmoc-Val-Cit-PAB is a cleavable linker for antibody-drug-conjugation (ADC).

2-Aminoethyl-mono-amide-DOTA-tris(tBu ester) is a macrocycle DOTA derivative for tumor pretargeting.

Ozogamicin is an antibody-drug conjugate Linker.

PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab).

Mc-Val-Cit-PAB-Cl is a cleavable ADC linker. Mc-Val-Cit-PAB-Cl can be used to conjugate MMAE and antibody to form antibody-MC-vc-MMAE .

Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC peptide linker.

Biotin-PEG3-amineis PEG derivative containing a biotin group and a terminal primary amine group.

CL2 Linker is a cleavableADC linker. CL2-SN-38 and CL2A-SN-38 are equivalent in drug substitution (~6), cell binding (Kd ~1.2 nM), cytotoxicity (IC50 ~2.2 nM), and serum stability in vitro (t1/2 ~20 hours).

L2A is a claevable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond. Labetuzumab govitecan used this linker.

EC089 is a cleavable linker used in conjugates of tubulysins and folates, and extracted from patent WO2011069116A1.

EC1167 is the linker for EC1169. EC1169 is prostate-specific membrane antigen targeting-tubulysin conjugate. EC1169 has the potential to treat recurrent metastatic, castration-resistant prostate cancer (MCRPC).

6-O-2-Propyn-1-yl-D-galactose is a nonclaevable glycolinker for the functionalization of cytotoxic drugs and applications in antibody-drug conjugation.

Fmoc-PEA (Example 1-2) is a used as a cleavable linker for antibody-drug conjugates (ADC).

SPP is a cleavable disulfide linker, can be used to form cytotoxic compound- linker conjugate.

AMAS is a nonclaevable heterobifunctional crosslinker with NHS ester and maleimide groups that allows covalent conjugation of amine- and sulfhydryl-containing molecules.

DBCO-NHS ester 2 is a cleavable linker that is used for making antibody-drug conjugate (ADC). DBCO-NHS ester 2 is a derivative of Dibenzylcyclooctyne (DBCO) used in copper-free click chemistry.

Fmoc-Phe-Lys(Boc)-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Macropa-NCS is conjugated to trastuzumab as well as to the prostate-specific membrane antigen-targeting compound RPS-070. A promising therapeutic radionuclide applied in the treatment of soft-tissue metastases.

Succinic anhydride is a cyclic anhydride and a nonclaevable ADC linker extracted from patent WO2009064913A1. Succinic anhydride can react with compound 4 of the patent to link the prodrug to an amine or hydroxy 1 group of a targeting polypeptide.

Mal-amido-PEG8-C2-acid (example 142) is a nonclaevable ADC linker, extracted from patent US2018339985.

MC-Val-Cit-PAB is a cathepsin cleavable ADC linker that is used for making antibody-drug conjugate. FDA approved drugs such as brentuximab vedotin use this linker.

SPDP (SPDP Crosslinker) is a short-chain crosslinker for amine-to-sulfhydryl conjugation via NHS-ester and pyridyldithiol reactive groups that form cleavable (reducible) disulfide bonds with cysteine sulfhydryls. It is a glutathione cleavable ADC linker used for the antibody-drug conjugates (ADCs).

Vipivotide tetraxetan Linker (PSMA-617 Linker) is a nonclaevable peptide linker for synthesis of Vipivotide tetraxetan (PSMA-617).

SMCC is a protein crosslinker. SMCC-conjugated antigen coupled spleen cells to induce antigen-specific immune responses.

SPDB is a glutathione cleavable ADC linker used for the antibody-drug conjugate (ADCs).

Val-cit-PAB-OH is a cleavable ADC linker.

FBN33428, also known as Fmoc-Phe-?Lys(Boc)-PAB; is a Hydrolyzable linker for making ADC conjugate

Val-Lys(Boc)-PAB is a ADC linker.

MC-Gly-Gly-Phe is a cleavable linker used for antibody-drug conjugates (ADC).

Boc-Gly-Gly-Phe-Gly-OH is a protease cleavable linker used for the antibody-drug conjugate (ADC).

Boc-Dap-NE is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Mc-Gly-Gly-Phe-Gly-PAB-OH (Mc-GGFG-PAB-OH) is a cleavable ADC linker used for antibody-drug conjugates (ADCs).

BS2G Crosslinker Disodium is an amine-reactive homobifunctional crosslinker that targets amine groups on proteins and peptides. This reagent facilitates the stable conjugation of proteins, peptides, and biomolecules, making it valuable in the development of antibody-drug conjugates (ADCs). Its application extends to various biochemical research and therapeutic studies, where precise linkage is essential for functionality.

MC-VC-PAB-Tubulysin M is a synthetic antibody-drug conjugate (ADC) linker that combines the potent tubulin polymerization inhibitor, Tubulysin M, with the cleavable linker MC-vc-PAB. This conjugate targets and disrupts microtubule dynamics, offering potential for selective cytotoxicity in cancer treatment. It is primarily utilized in the development of ADCs to enhance therapeutic efficacy while minimizing off-target effects in various cancer research applications.

diSPhMC-Asn-Pro-Val-PABC-MMAE is an effective ADC linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the selective delivery of therapeutic agents to target cells, enhancing the efficacy of cancer treatment while minimizing systemic toxicity. It is suitable for applications in targeted therapy research and the development of novel ADC formulations.

Asn-Pro-Val-PABC-MMAE TFA is an effective ADC linker designed for the development of antibody-drug conjugates (ADCs). This compound facilitates the conjugation of cytotoxic drugs to antibodies, enhancing targeted delivery and therapeutic efficacy. It is a valuable tool for researchers focused on developing novel ADC therapies for cancer treatment and other diseases.

DeBoc-Cabazitaxel serves as a versatile ADC linker, facilitating the conjugation of antibodies to cytotoxic agents for targeted therapy. This compound enhances the efficacy of antibody-drug conjugates (ADCs) by enabling selective delivery to tumor cells while minimizing off-target effects. It is particularly valuable in the development of novel cancer therapies, supporting research in targeted anti-tumor strategies.

Dap-NE is an intermediate reagent specifically designed for use in the synthesis of antibody-drug conjugates (ADCs), particularly the cytotoxic agent Monomethyl auristatin E. Its role as a linker plays a critical part in ensuring the efficient delivery of therapeutic agents to targeted cells, enhancing the efficacy of the ADC. This compound is essential for researchers investigating novel ADC formulations and their applications in cancer therapeutics.

SC209 intermediate-2 is an ADC linker designed for use in antibody-drug conjugate (ADC) synthesis. This compound serves as an essential intermediate for the cytotoxin SC209, enabling targeted delivery of therapeutic agents to cancer cells. SC209 intermediate-2 plays a crucial role in enhancing the efficacy of ADCs in research applications focused on cancer treatment and drug development.

BCN-linker-DXd 2 is a specialized ADC (antibody-drug conjugate) linker designed for targeted delivery of cytotoxic agents to cancer cells. This compound facilitates the conjugation of drugs to antibodies, enhancing specificity and reducing off-target effects in cancer therapy. It is applicable in research focused on ADC development and optimization for improved therapeutic efficacy against various types of tumors.

Mal-PEG8-Val-Ala-PAB-Exatecan is an anti-Nectin-4 antibody-drug conjugate (ADC) linker designed to facilitate targeted delivery of chemotherapeutic agents. This compound enables precise conjugation to Nectin-4 polypeptides, allowing for enhanced therapeutic efficacy in cancer research applications. Its unique structure promotes stability and release characteristics, making it suitable for studying the effects of ADCs in various tumor models.

SuO-Glu-Val-Cit-PAB-MMAE is a cleavable antibody-drug conjugate (ADC) linker that combines SuO-Glu-Val-Cit-PAB with the potent tubulin inhibitor MMAE. This compound enables targeted delivery of MMAE via ADC technology, facilitating selective cytotoxicity in cancer research. SuO-Glu-Val-Cit-PAB-MMAE is suitable for the synthesis of ADCs, providing a strategic approach to enhance therapeutic efficacy while minimizing off-target effects.

Amino-PEG4-Val-Cit-PAB-MMAE is a cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates selective drug delivery by connecting antibodies to the cytotoxic agent MMAE, enhancing therapeutic efficacy while minimizing off-target effects. Its PEG4 moiety ensures improved solubility and stability, making it suitable for research applications in cancer therapy and targeted delivery systems.

Glucocorticoid receptor agonist-1 phosphate(2,6-difluoro) Ala-Ala-Br serves as a versatile drug-linker conjugate for antibody-drug conjugate (ADC) applications. This reagent enables the synthesis of conjugates targeting the CD40 antigen, facilitating the development of targeted therapies. Its unique structure supports the design of PROTACs and other innovative bio-conjugates, contributing to advances in cancer research and immunotherapy.

OH-Glu-Val-Cit-PAB-MMAE is a cleavable antibody-drug conjugate (ADC) linker that incorporates a potent tubulin inhibitor, MMAE. This compound is designed for the synthesis of ADCs, facilitating targeted delivery of cytotoxic agents to cancer cells. Its unique structure allows for selective release of MMAE, enhancing therapeutic efficacy while minimizing off-target effects. This reagent is valuable for researchers developing novel ADCs in the field of cancer treatment.

IM-2 is a potent ADC linker designed for the synthesis of antibody-drug conjugates (ADCs). It facilitates the efficient conjugation of cytotoxic agents to antibodies, enhancing targeted delivery to cancer cells while minimizing systemic toxicity. This reagent is ideal for research applications focused on developing novel therapeutic modalities in oncology.

Exatecan-mpGNNG is a linker-payload component designed for use in antibody-drug conjugates (ADCs). It integrates Exatecan, a highly effective inhibitor of topoisomerase I, facilitating targeted delivery of therapeutic agents to cancer cells. This compound is particularly relevant for research applications focusing on ADC development and the evaluation of antitumor efficacy.

Fmoc-Val-Cit-PAB-MMAF-OtBu is a linker compound designed for the conjugation of MMAF (monomethyl auristatin F) to antibodies, facilitating the formation of antibody-drug conjugates (ADCs). This versatile linker allows for the selective delivery of the cytotoxic agent to tumor cells, enhancing anti-tumor efficacy while minimizing systemic toxicity. Fmoc-Val-Cit-PAB-MMAF-OtBu is suitable for research applications in ADC development and cancer therapeutics.

Fmoc-Phe-Lys(Trt)-PAB-PNP is a cleavable linker specifically designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the stable attachment of cytotoxic agents to antibodies while allowing for selective release in the target environment. Its design enables enhanced efficacy in targeted cancer therapy, making it a valuable tool for researchers developing ADCs.